While the vast majority of IOLs implanted to take care of cataracts are monofocal lenses, ZEISS offers shaped the market with its multifocal intraocular lenses significantly. The most recent addition to the portfolio of multifocal lenses, that offer excellent eyesight at near, long and intermediate distances, the AT LISA tri toric, is the only zoom lens of its kind to bear a CE mark. ZEISS offers cataract surgeons a complete integrated solution to take care of cataracts from diagnosis to aftercare and surgery. About 70 % of most cataract patients come in contact with a ZEISS product..The working result fell by 41.1 % to EUR 750 million . Special products totaled minus EUR 762 million . Special products additionally comprised impairment losses on intangible possessions and restructuring charges . EBIT before particular items increased by 6.7 % to EUR 1,512 million . Earnings before curiosity, taxes, depreciation and amortization – before special products – elevated by 6.7 % to EUR 2,172 million . Positive currency results contributed around EUR 70 million to the figure. Due to the high special products, net gain declined by 33.9 % to EUR 494 million .